Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to Cialis® (Tadalafil), a leading men's health product from Eli Lilly and Company ('Lilly') in Hong Kong, Macau and South Korea.

裕利医药（Zuellig Pharma），亚洲领先的医疗保健解决方案公司，今天宣布已从礼来公司（Eli Lilly and Company，简称“礼来”）收购了希爱力（Cialis®，通用名：他达拉非）在香港、澳门和韩国的所有权利、所有权和利益。希爱力是礼来公司的一款领先的男性健康产品。

Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight.

收购完成后，裕利医药将拥有治疗勃起功能障碍（ED）和良性前列腺增生（BPH）的药物Cialis®的商标、上市许可及许可生产技术，在亚洲11个市场开展业务，并将其所有权从原来的8个市场扩展到新增的3个市场。

Zuellig Pharma will also continue to promote and distribute the brand in these markets..

裕利医药还将继续在这些市场推广和分销该品牌。

The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma's strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company..

Cialis®所有权的扩大将使亚洲受勃起功能障碍和良性前列腺增生影响的大量男性更容易获得该药物。此次收购也符合裕利医药作为一家综合医疗解决方案公司建立强大的自有处方医疗产品组合的战略重点。

'Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,' said John Graham, CEO of Zuellig Pharma..

“我们在另外三个市场对Cialis®的收购建立在两年前奠定的坚实基础之上，彰显了我们通过商业能力和深厚的专业知识有效扩展可信赖品牌的成功经验。随着我们扩大业务范围，我们将继续专注于实现可持续增长，并推进我们的使命，即使亚洲社区更容易获得急需的医疗保健解决方案，”Zuellig Pharma首席执行官John Graham表示。

About Zuellig Pharma

关于裕利医药

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region.

裕利医药是亚洲领先的医疗保健解决方案公司，我们的宗旨是让所服务的社区更容易获得医疗保健。我们提供世界级的分销、商业化和临床试验支持服务，依托强大的创新文化，满足该地区不断增长的医疗保健需求。

The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world..

公司成立于一百年前，现已发展成为一家覆盖18个市场、拥有超过12,000名员工的数十亿美元企业。我们的团队为超过20万家医疗机构提供服务，并与450多家客户合作，其中包括全球前20大制药公司。

The issuer is solely responsible for the content of this announcement.

发行人对本公告的内容负全责。

Media Contact(s)

媒体联系人

Angelene Chong

钟安洁

Head of Corporate Communications

企业传播主管

achongam@zuelligpharma.com

achongam@zuelligpharma.com

Sandpiper, on behalf of Zuellig Pharma

鹬鸟，代表裕利医药

zuelligpharma@sandpipercomms.com

至灵制药@山地鹤通讯.com